Janus Henderson Group PLC Cuts Stock Holdings in Merus (NASDAQ:MRUS)

Janus Henderson Group PLC trimmed its holdings in shares of Merus (NASDAQ:MRUS) by 98.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,890 shares of the biotechnology company’s stock after selling 998,117 shares during the quarter. Janus Henderson Group PLC’s holdings in Merus were worth $944,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of MRUS. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 489 shares during the last quarter. nVerses Capital LLC grew its holdings in Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,500 shares during the last quarter. US Bancorp DE acquired a new position in shares of Merus during the third quarter worth $103,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Merus by 41.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,847 shares of the biotechnology company’s stock valued at $523,000 after purchasing an additional 2,572 shares during the last quarter. Finally, XTX Topco Ltd boosted its position in shares of Merus by 54.3% in the 2nd quarter. XTX Topco Ltd now owns 11,166 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 3,931 shares in the last quarter. Institutional investors own 96.14% of the company’s stock.

Merus Stock Up 3.3 %

Merus stock opened at $42.83 on Friday. The business’s 50-day moving average price is $48.97 and its 200 day moving average price is $51.52. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -10.84 and a beta of 1.07. Merus has a 52 week low of $24.07 and a 52 week high of $61.61.

Merus (NASDAQ:MRUS) last issued its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The firm had revenue of $11.77 million for the quarter, compared to analyst estimates of $9.11 million. Equities analysts expect that Merus will post -3.89 EPS for the current year.

Analyst Ratings Changes

MRUS has been the subject of a number of research analyst reports. The Goldman Sachs Group began coverage on Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 2nd. UBS Group started coverage on shares of Merus in a research report on Thursday, October 24th. They set a “buy” rating and a $72.00 target price on the stock. Citigroup raised their price target on shares of Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Finally, Guggenheim reissued a “buy” rating and set a $109.00 price objective (down from $111.00) on shares of Merus in a report on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $85.64.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.